Holen Sie sich die Stockscreener-App
106.66
4.78%
4.87
Handel nachbörslich:
106.22
-0.44
-0.41%
Incyte Corp Aktie (INCY) Neueste Nachrichten
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
Positive top-line results for Incyte’s tafasitamab in DLBCL - The Pharma Letter
Incyte stock rises as Stifel reiterates Buy rating on positive trial data - Investing.com India
Why Is Incyte Stock Gaining Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's blood cancer therapy slows disease progression in trial - Reuters
The Bull Case For Incyte (INCY) Could Change Following Positive frontMIND Phase 3 DLBCL Results - simplywall.st
Incyte (INCY) Achieves Phase 3 Success with Tafasitamab in Lymph - GuruFocus
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Incyte (INCY) Achieves Key Milestones in Phase 3 Lymphoma Study - GuruFocus
Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com - Investing.com Australia
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi - Business Wire
Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
INCYTE CORPORATION CMNRo Khanna Congressional Trade on May. 02, 2017 - Quiver Quantitative
Incyte takes JPMorgan stage as investors look for pipeline signals - MSN
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals - MyChesCo
Incyte Corporation (NASDAQ:INCY) Nasdaq Index Fund Pathway Science - Kalkine Media
Incyte Corporation (NASDAQ:INCY) Receives Average Rating of "Hold" from Analysts - MarketBeat
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options - MyChesCo
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co. - MarketBeat
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pacer Advisors Inc. Grows Position in Incyte Corporation $INCY - MarketBeat
Swedbank AB Decreases Stock Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Is It Too Late To Consider Incyte After A 45% Rally In 2025? - Yahoo Finance
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader - MyChesCo
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz - simplywall.st
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan - Yahoo Finance
Thomas Tray Sells 600 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (NASDAQ:INCY) Insider Sells $277,400.00 in Stock - MarketBeat
Incyte principal accounting officer Tray Thomas sells shares worth $336k - Investing.com
Incyte Corp Principal Accounting Officer Sells Shares - TradingView — Track All Markets
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (NASDAQ:INCY) Stock Price Down 3.4%Time to Sell? - MarketBeat
Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi - RTTNews
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer - Kalkine Media
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido - PharmiWeb.com
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - PharmiWeb.com
Japan Approves Incyte's (INCY) Zynyz for First-Line SCAC Treatme - GuruFocus
Incyte (INCY) Secures Japanese Approval for Minjuvi Combination Therapy - GuruFocus
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Entry Recap: Can Incyte Corporation stock beat market expectations this quarterJuly 2025 Snapshot & Weekly Top Gainers Trade List - moha.gov.vn
Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer - MyChesCo
VP Iyengar Files To Sell 52,941 Of Incyte Corp [INCY] - TradingView — Track All Markets
Why Incyte Corporation (ICY) stock stays on buy listsMarket Performance Report & High Conviction Buy Zone Alerts - DonanımHaber
Can Incyte Corporation stock hit analyst price targetsWatch List & Free Weekly Watchlist of Top Performers - DonanımHaber
Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY) - simplywall.st
Incyte Corp EVP Sells Over $5.6 Million in Company Stock - TradingView — Track All Markets
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Yahoo Finance
Incyte to Present at Upcoming Investor Conference - Business Wire
EC approves Incyte’s Minjuvi combo for follicular lymphoma - Pharmaceutical Technology
Incyte wins European approval of Minjuvi in FL - The Pharma Letter
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - BioSpace
Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma - Nasdaq
Incyte (INCY) Gains EU Approval for Minjuvi in Follicular Lympho - GuruFocus
Minjuvi approved in EU for relapsed follicular lymphoma treatment - Investing.com
Incyte (INCY) Gains European Approval for Minjuvi in New Cancer Treatment - GuruFocus
4.09%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):